Clinical Outcomes and Response to Vericiguat According to Index Heart Failure EventCarolyn S.P. Lam, Carmine G. De Pasquale, Anna Giczewska et al.|JAMA Cardiology|2020Cited by 84
Vericiguat in patients with chronic heart failure and reduced ejection fraction (VICTOR): a double-blind, placebo-controlled, randomised, phase 3 trialJaved Butler, Imran Zainal Abidin, Ciaran J. McMullan et al.|The Lancet|2025Cited by 77
Vericiguat for patients with heart failure and reduced ejection fraction across the risk spectrum: an individual participant data analysis of the VICTORIA and VICTOR trialsFaı̈ez Zannad, Nicholas Ryan, Christopher M. O’Connor et al.|The Lancet|2025Cited by 39
Consensus Statement of Indian Academy of Pediatrics on Early Childhood DevelopmentKetan Bharadva, Somashekhar Nimbalkar, Digant Shastri et al.|Indian Pediatrics|2020Cited by 17
Index Event, Clinical Outcomes and Response to Vericiguat in the Victoria TrialCarolyn S.P. Lam, Paul W. Armstrong, Burkert Pieske et al.|Unknown|2020Cited by 0